Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody

doi:10.3969/j.issn.1673-8640.2023.07.010

Abstract

Abstract:

Objective To investigate the clinical role of platelet-to-lymphocyte ratio（PLR）in patients with ankylosing spondylitis（AS）combined with positive antinuclear antibody（ANA）. Methods A total of 132 patients with AS in the Affiliated Hospital of Xuzhou Medical University from January 2018 to November 2021 were enrolled. There were 39 cases of ANA positivity and 93 cases of ANA negativity. Totally，98 healthy subjects during the same period were enrolled as control group. The difference of general clinical data between the 2 groups were compared. Spearman correlation analysis was used to evaluate the correlation between indexes. Multivariate Logistic regression analysis was used to investigate the independent risk factors of ANA positivity in AS patients. Receiver operating characteristic（ROC）curve was used to evaluate the risk predictive value of each index for AS combined with ANA positivity. The index difference of ANA positive and negative patients after treatment with adalimumab was analyzed. Results The differences of lymphocytes，platelets，monocytes，red blood cell distribution width（RDW），PLR，monocyte-to-lymphocyte ratio（MLR），neutrophil-to-lymphocyte ratio（NLR），immunoglobulin（Ig） G，IgA，IgM between AS group and healthy control group were statistically significant（P<0.05）. RDW was positively correlated with erythrocyte sedimentation rate（ESR）（r=0.189，P=0.034）. PLR，MLR and NLR were positively correlated with ESR and C-reactive protein（CRP）（P<0.05）. Mean platelet volume（MPV） was negatively correlated with ESR and CRP（r=-0.382 and -0.385，P<0.001）. There was statistical significance in age，ESR，CRP，PLR，IgG，lymphocyte count and disease course between ANA positive and negative groups（P<0.05）. For ANA positive patients，PLR was positively correlated with ESR and CRP（r=0.579 and 0.691，P<0.001）. PLR and disease course are independent risk factors for AS combined with ANA positivity（P<0.05）. The adalimumab treatment effect of patients with positive and negative ANA was followed up，and there was statistical significance in RDW，PLR，ESR and CRP between the 2 groups（P<0.05）. Conclusions The ANA positive patients with AS may have high disease activity and poor treatment effect. PLR may play a clinical guiding role in AS patients with ANA positivity.

Key words: Ankylosing spondylitis, Platelet-to-lymphocyte ratio, Antinuclear antibody

CLC Number:

R446.11

DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody[J]. Laboratory Medicine, 2023, 38(7): 669-674.

Figures/Tables 6

References 14

[1]	中华医学会风湿病学分会. 强直性脊柱炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010, 14(8):557-559.
[2]	陈水绵, 游玉权, 张红凤, 等. 强直性脊柱炎患者抗核抗体检测结果及临床意义分析[J]. 检验医学与临床, 2021, 18(16):2314-2317.
[3]	MAHLER M, MERONI P L, BOSSUYT X, et al. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies[J]. J Immunol Res, 2014, 2014:315179.
[4]	李琳芸, 彭长华, 梅冰, 等. 中国人群强直性脊柱炎与ERAP-1基因多态性的相关性Meta分析[J]. 检验医学, 2018, 33(6):481-485.
[5]	SCHNEEBERGER E E, ZAMORA N, CITERA G. SASDAS(simplified version of ankylosing spondylitis disease activity score)-ESR performance and development of SASDAS-CRP and their agreement with ASDAS-ESR and ASDAS-CRP in patients with ankylosing spondylitis[J]. Clin Rheumatol, 2016, 35(11):2865-2866. DOI URL
[6]	YANG Z, REN Y, LIU D, et al. Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile:data from a tertiary hospital in Shanghai,China[J]. APMIS, 2016, 124(9):805-811. DOI URL
[7]	GOODNOW C C. Multistep pathogenesis of autoimmune disease[J]. Cell, 2007, 130(1):25-35. DOI PMID
[8]	GÖKMEN F, AKBAL A, REORLU H, et al. Neutrophil-lymphocyte ratio connected to treatment options and inflammation markers of ankylosing spondylitis[J]. J Clin Lab Anal, 2015, 29(4):294-298. DOI PMID
[9]	AL-OSAMI M H, AWADH N I, KHALID K B, et al. Neutrophil/lymphocyte and platelet/lymphocyte ratios as potential markers of disease activity in patients with ankylosing spondylitis:a case-control study[J]. Adv Rheumatol, 2020, 60(1):13. DOI
[10]	ADAMSSON ERYD S, BORNÉ Y, MELANDER O, et al. Red blood cell distribution width is associated with incidence of atrial fibrillation[J]. J Intern Med, 2014, 275(1):84-92. DOI PMID
[11]	SONG C S, PARK D I, YOON M Y, et al. Association between red cell distribution width and disease activity in patients with inflammatory bowel disease[J]. Dig Dis Sci, 2012, 57(4):1033-1038. DOI URL
[12]	ZEB A, KHURSHID S, BANO S, et al. The role of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as markers of disease activity in ankylosing spondylitis[J]. Cureus, 2019, 11(10):e6025.
[13]	RAYES J, BOURNE J H, BRILL A, et al. The dual role of platelet-innate immune cell interactions in thrombo-inflammation[J]. Res Pract Thromb Haemost, 2019, 4(1):23-35. DOI URL
[14]	XU S, MA Y, WU M, et al. Neutrophil lymphocyte ratio in patients with ankylosing spondylitis:a systematic review and meta-analysis[J]. Mod Rheumatol, 2020, 30(1):141-148. DOI URL

组别	例数	年龄/岁	性别		淋巴细胞计数/（×10⁹/L）	中性粒细胞计数/（×10⁹/L）	单核细胞计数/ （×10⁹/L）
组别	例数	年龄/岁	男/例	女/例	淋巴细胞计数/（×10⁹/L）	中性粒细胞计数/（×10⁹/L）	单核细胞计数/ （×10⁹/L）
AS组	132	41.50（30.00，50.25）	75	57	1.90（1.50，2.20）	3.42（2.91，4.54）	0.37（0.28，0.49）
正常对照组	98	45.50（33.00，51.00）	61	37	2.00（1.60，2.43）	3.38（2.55，4.20）	0.35（0.27，0.42）
统计值		-1.564	0.685		-2.332	-1.957	-2.166
P值		0.118	0.408		0.020	0.050	0.030

组别	例数	年龄/岁	性别		淋巴细胞计数/（×10⁹/L）	中性粒细胞计数/（×10⁹/L）	单核细胞计数/ （×10⁹/L）
组别	例数	年龄/岁	男/例	女/例	淋巴细胞计数/（×10⁹/L）	中性粒细胞计数/（×10⁹/L）	单核细胞计数/ （×10⁹/L）
AS组	132	41.50（30.00，50.25）	75	57	1.90（1.50，2.20）	3.42（2.91，4.54）	0.37（0.28，0.49）
正常对照组	98	45.50（33.00，51.00）	61	37	2.00（1.60，2.43）	3.38（2.55，4.20）	0.35（0.27，0.42）
统计值		-1.564	0.685		-2.332	-1.957	-2.166
P值		0.118	0.408		0.020	0.050	0.030

项目	RDW		MPV		PLR		MLR		NLR
项目	r值	P值	r值	P值	r值	P值	r值	P值	r值	P值
ESR	0.189	0.034	-0.382	<0.001	0.583	<0.001	0.285	0.001	0.445	<0.001
CRP	0.146	0.109	-0.385	<0.001	0.559	<0.001	0.343	<0.001	0.502	<0.001
lgG	0.015	0.869	-0.261	0.003	0.325	<0.001	0.105	0.242	0.177	0.048
lgA	0.063	0.482	-0.194	0.030	0.294	0.001	0.099	0.270	0.218	0.014
lgM	0.022	0.810	-0.145	0.105	0.143	0.110	0.044	0.628	0.031	0.732

项目	RDW		MPV		PLR		MLR		NLR
项目	r值	P值	r值	P值	r值	P值	r值	P值	r值	P值
ESR	0.189	0.034	-0.382	<0.001	0.583	<0.001	0.285	0.001	0.445	<0.001
CRP	0.146	0.109	-0.385	<0.001	0.559	<0.001	0.343	<0.001	0.502	<0.001
lgG	0.015	0.869	-0.261	0.003	0.325	<0.001	0.105	0.242	0.177	0.048
lgA	0.063	0.482	-0.194	0.030	0.294	0.001	0.099	0.270	0.218	0.014
lgM	0.022	0.810	-0.145	0.105	0.143	0.110	0.044	0.628	0.031	0.732

组别	例数	年龄/岁	性别		病程/年	淋巴细胞计数/（×10⁹/L）	中性粒细胞计数/（×10⁹/L）	单核细胞计数/（×10⁹/L）
组别	例数	年龄/岁	男/例	女/例	病程/年	淋巴细胞计数/（×10⁹/L）	中性粒细胞计数/（×10⁹/L）	单核细胞计数/（×10⁹/L）
ANA阳性组	39	50.11±17.67	16	23	10.00（0.50，30.00）	1.60（1.20，2.00）	3.64（2.99，4.74）	0.34±0.12
ANA阴性组	93	39.38±14.71	55	38	2.00（0.42，10.00）	1.80（1.50，2.10）	3.55（2.96，4.70）	0.40±0.17
统计值		4.419	3.627		-2.464	-2.574	-0.187	-1.236
P值		<0.001	0.057		0.014	0.010	0.852	0.219